The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...
Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback